2020 Annual Report
As the HIV epidemic changes over time, and new pandemics continue to emerge, TAG continues to evolve while remaining true to our activist roots. We partner with the most affected communities in the U.S. and around the world.
In Memoriam – Marco Castro-Bojorquez
We at Treatment Action Group (TAG) deeply mourn the loss of Marco Castro-Bojorquez, a visionary HIV and human rights activist, artist and filmmaker. Marco’s light shined brightly throughout his work and lifted up all around him.
TAG Urges Governor to Sign New York State Bill Expanding Adult Vaccines Available in Pharmacies
The bill, S4807A (Stavisky) / A6476A (Hyndman), improves preventive viral hepatitis vaccine access, and is particularly important for people who use drugs and unhoused New Yorkers.
ACT NOW: END AIDS
ACT NOW: END AIDS (ANEA) is a national coalition of community-based organizations, health departments, national policy partners, and activists committed to ending the HIV epidemic in the United States. TAG is proud to be a co-founder and facilitator for ANEA.
Time for $5 Coalition Statement: Cepheid’s Updated GeneXpert Pricing Does Not Address Country Needs
The Time for $5 Coalition, comprised of over 150 civil society organizations globally, calls out Cepheid for the company’s insufficient and self-serving GeneXpert pricing packages for low- and middle-income countries (LMICs), announced May 6, 2021.
TAG Welcomes U.S. Government Support of Intellectual Property Flexibilities to Enable COVID-19 Vaccine Access
Treatment Action Group (TAG) applauds the U.S. government’s decision to support the India-South Africa proposed waiver of certain intellectual property rights to enable equitable access to life-saving interventions for COVID-19.
TAG Comments on NIST’s Proposed Rulemaking Changes
TAG submitted comments in response to the National Institute of Standards and Technology's (NIST) proposed change to rulemaking, strongly opposing amendments to remove crucial public health safeguards from the Bayh-Dole Act. March-in rights and other provisions to hold manufacturers accountable when federally funded inventions are exorbitantly priced and are critically important to public health and the right to science.
Civil Society Letter to Donors, Countries, and Health Actors to Improve Access to GeneXpert and Other Diagnostics
TAG led an open letter appealing to donors, countries, and health actors to improve access to GeneXpert and other diagnostics for COVID-19, TB, HIV, HBV, HCV, and other diseases by applying collective leverage in negotiations with Cepheid for lower prices and sufficient volumes; establishing cost-of-goods-sold (COGS)-plus and volume-based pricing for diagnostics as a global norm; and increasing investments in alternative rapid molecular tests to promote competition and improve access.
How Lessons Learned from the HIV Epidemic Can Inform Efforts to Address the COVID-19 Pandemic Through a Racial Equity Lens
Join us on March 15, 2021 at 4:00 p.m. EST for this free webinar, which will discuss a variety of issues concerning disenfranchised communities being disproportionately affected by COVID-19.
Civil Society Letter to Cepheid Requesting Lower Prices for Xpert SARS-CoV-2 Tests and Increased Volumes Distributed to LMICs
February 25, 2021 — TAG signed onto this letter requesting that diagnostics company Cepheid increase access to Xpert SARS-CoV-2 tests in low- and middle-income countries (LMICs) by committing a greater proportion of its SARS-CoV-2 test manufacturing capacity to LMICs and…